A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
Status:
Not yet recruiting
Trial end date:
2022-03-20
Target enrollment:
Participant gender:
Summary
In addition, studies have found that indobufen can inhibit coagulation function in rats.
Compared with aspirin, the duration of antiplatelet efficacy of indobufen was shorter, and
the platelet function recovered completely 24 hours after drug withdrawal. However, there are
few studies on the antiplatelet efficacy of indobufen. The investigators' previous study
found that the inhibitory effect of indobufen 100 mg Bid on COX system in atherosclerosis or
healthy volunteers was equivalent to that of aspirin 100 mg QD, but the inhibitory effect on
platelet COX-1 channel was significantly weaker than that of aspirin 100 mg QD. In view of
this, this study intends to investigate the antiplatelet effect of indobufen 200 mg Bid in
patients with coronary atherosclerosis by comparing it with conventional-dose aspirin 100 mg
QD.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University